The role of vitamin D and its supplementation in sarcoidosis – current status
DOI:
https://doi.org/10.15584/ejcem.2025.2.16Keywords:
bone mineral density, disease course, hypercalcemia, sarcoidosis, supplementation, vitamin DAbstract
Introduction and aim. Sarcoidosis is a chronic autoimmune-related inflammatory disease characterized by non-caseating granuloma formation. The macrophages accumulating in granulomas express increased 1alpha hydroxylase activity. Increased extrarenal 1,25-dihydroxyvitamin D synthesis can lead to hypercalcemia and its complications. However, 25-hydroxyvitamin D deficiency and insufficiency are virtually universal among sarcoidosis patients. The aim of this study was to explain the complex role of vitamin D and to its metabolites and discuss the possible benefits and risks associated with the administration of exogenous vitamin D to patients with sarcoidosis.
Material and methods. PubMed and Scopus databases were searched for reviews about The role of vitamin D and its supplementation in sarcoidosis. The authors have analyzed a total of 107 full-text articles published between January 2000 and November 2024, with additional articles identified by bibliography analysis.
Analysis of literature. The potential benefits of vitamin D supplementation in sarcoidosis are promising in terms of reducing the inflammatory response, counteracting disease progression, reducing bone fracture risk, and minimizing the pharmacotherapy needed for disease control. However, the risk of hypercalcemia should not be neglected.
Conclusion. Despite the increased risk of hypercalcemia, vitamin D supplementation in patients with sarcoidosis should be considered. Each patient’s benefits-to-risks ratio of vitamin D supplementation should be assessed individually and the inter vention should be closely monitored both before and during implementation.
Downloads
References
Carmona EM, Kalra S, Ryu JH. Pulmonary Sarcoidosis: Diagnosis and Treatment. Mayo Clin Proc. 2016;91(7):946-954. doi: 10.1016/J.MAYOCP.2016.03.004
Jain R, Yadav D, Puranik N, Guleria R, Jin JO. Sarcoidosis: Causes, Diagnosis, Clinical Features, and Treatments. J Clin Med. 2020;9(4). doi: 10.3390/JCM9041081
Acharya NR, Browne EN, Rao N, Mochizuki M. Distinguishing Features of Ocular Sarcoidosis in an International Cohort of Uveitis Patients. Ophthalmology. 2018;125(1):119-126. doi: 10.1016/J.OPHTHA.2017.07.006
Fang C, Huang H, Xu Z. Immunological Evidence for the Role of Mycobacteria in Sarcoidosis: A Meta-Analysis. PLoS One. 2016;11(8). doi: 10.1371/JOURNAL.PONE.0154716
Belperio JA, Fishbein MC, Abtin F, Channick J, Balasubramanian SA, Lynch JP. Pulmonary sarcoidosis: A comprehensive review: Past to present. J Autoimmun. 2024; 149:103107. doi: 10.1016/J.JAUT.2023.103107
Jayakrishnan B, Al-Busaidi N, Al-Mubaihsi S, Al-Rawas O. Sarcoidosis in the Middle East. Ann Thorac Med. 2019;14(2):106-115. doi: 10.4103/ATM.ATM_227_18
Cozier Y, Ruiz-Narvaez E, McKinnon C, Berman J, Rosenberg L, Palmer J. Replication of genetic loci for sarcoidosis in US black women: data from the Black Women’s Health Study. Hum Genet. 2013;132(7):803-810. doi: 10.1007/S00439-013-1292-5
Hunninghake GW, Costabel U, Ando M, et al. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2):736-755. doi: 10.1164/AJRCCM.160.2.ATS4-99
Judson MA. The treatment of sarcoidosis: translating the European respiratory guidelines into clinical practice. Curr Opin Pulm Med. 2022;28(5):451-460. doi: 10.1097/MCP.0000000000000896
Judson MA. The treatment of sarcoidosis: translating the European respiratory guidelines into clinical practice. Curr Opin Pulm Med. 2022;28(5):451-460. doi: 10.1097/MCP.0000000000000896
Sun M, Wu X, Yu Y, et al. Disorders of Calcium and Phosphorus Metabolism and the Proteomics/Metabolomics-Based Research. Front Cell Dev Biol. 2020;8:576110. doi: 10.3389/FCELL.2020.576110
Karakaya B, van der Vis JJ, Veltkamp M, Biesma DH, Grutters JC, van Moorsel CHM. ANXA11 rs1049550 Associates with Löfgren’s Syndrome and Chronic Sarcoidosis Patients. Cells. 2022;11(9):1557. doi: 10.3390/CELLS11091557
Feng X, Zang S, Yang Y, et al. Annexin A11 (ANXA11) gene polymorphisms are associated with sarcoidosis in a Han Chinese population: a case-control study. BMJ Open. 2014;4(7):e004466. doi: 10.1136/BMJOPEN-2013-004466
Kishore A, Sikorova K, Kocourkova L, et al. Evaluation of genetic risk, its clinical manifestation and disease management based on 18 susceptibility gene markers among West-Slavonic patients with sarcoidosis. Gene. 2023;878:147577. doi: 10.1016/J.GENE.2023.147577
Zhang H, Costabel U, Dai H. The Role of Diverse Immune Cells in Sarcoidosis. Front Immunol. 2021;12:788502. doi: 10.3389/FIMMU.2021.788502
Gupta D, Agarwal R, Aggarwal AN, Jindal SK. Sarcoidosis and tuberculosis: the same disease with different manifestations or similar manifestations of different disorders. Curr Opin Pulm Med. 2012;18(5):506-516. doi: 10.1097/MCP.0B013E3283560809
Fraser SD, Sadofsky LR, Kaye PM, Hart SP. Reduced expression of monocyte CD200R is associated with enhanced proinflammatory cytokine production in sarcoidosis. Sci Rep. 2016;6:38689. doi: 10.1038/SREP38689
Kamphuis LS, Van Zelm MC, Lam KH, et al. Perigranuloma localization and abnormal maturation of B cells: emerging key players in sarcoidosis? Am J Respir Crit Care Med. 2013;187(4):406-416. doi: 10.1164/RCCM.201206-1024OC
Saussine A, Tazi A, Feuillet S, et al. Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PLoS One. 2012;7(8):43588. doi: 10.1371/JOURNAL.PONE.0043588
O’Sullivan F, Raftery T, van Weele M, et al. Sunshine is an Important Determinant of Vitamin D Status Even Among High-dose Supplement Users: Secondary Analysis of a Randomized Controlled Trial in Crohn’s Disease Patients. Photochem Photobiol. 2019;95(4):1060-1067. doi: 10.1111/PHP.13086
Meyer MB, Lee SM, Towne JM, et al. In Vivo Contribution of Cyp24a1 Promoter Vitamin D Response Elements. Endocrinology. 2024;165(11). doi: 10.1210/ENDOCR/BQAE134
Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess and manage. Semin Respir Crit Care Med. 2010;31(4):474-484. doi: 10.1055/s-0030-1262215
Hewison M. Vitamin D and the intracrinology of innate immunity. Mol Cell Endocrinol. 2010;321(2):103-111. doi: 10.1016/j.mce.2010.02.013
Szymczak I, Pawliczak R. The Active Metabolite of Vitamin D3 as a Potential Immunomodulator. Scand J Immunol. 2016;83(2):83-91. doi: 10.1111/SJI.12403
Gupta D, Agarwal R, Aggarwal AN, Jindal SK. Sarcoidosis and tuberculosis: the same disease with different manifestations or similar manifestations of different disorders. Curr Opin Pulm Med. 2012;18(5):506-516. doi: 10.1097/MCP.0B013E3283560809
Amagai R, Takahashi T, Terui H, et al. The Antimicrobial Peptide Cathelicidin Exerts Immunomodulatory Effects via Scavenger Receptors. Int J Mol Sci. 2023;24(1):875. doi: 10.3390/IJMS24010875
Yu J, Mookherjee N, Wee K, et al. Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways. J Immunol. 2007;179(11):7684-7691. doi: 10.4049/JIMMUNOL.179.11.7684
Barna BP, Culver DA, Kanchwala A, et al. Alveolar macrophage cathelicidin deficiency in severe sarcoidosis. J Innate Immun. 2012;4(5-6):569-578. doi: 10.1159/000339149
Panichi V, De Pietro S, Andreini B, et al. Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int. 1998;54(5):1463-1469. doi: 10.1046/J.1523-1755.1998.00152.X
Geldmeyer-Hilt K, Heine G, Hartmann B, Baumgrass R, Radbruch A, Worm M. 1,25-dihydroxyvitamin D3 impairs NF-κB activation in human naïve B cells. Biochem Biophys Res Commun. 2011;407(4):699-702. doi: 10.1016/J.BBRC.2011.03.078
Kamphuis LS, Van Zelm MC, Lam KH, et al. Perigranuloma localization and abnormal maturation of B cells: emerging key players in sarcoidosis? Am J Respir Crit Care Med. 2013;187(4):406-416. doi: 10.1164/RCCM.201206-1024OC
Saussine A, Tazi A, Feuillet S, et al. Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PLoS One. 2012;7(8). doi: 10.1371/JOURNAL.PONE.0043588
Haas J, Schwarz A, Korporal-Kuhnke M, Faller S, Jarius S, Wildemann B. Hypovitaminosis D upscales B-cell immunoreactivity in multiple sclerosis. J Neuroimmunol. 2016;294:18-26. doi: 10.1016/J.JNEUROIM.2016.03.011
Knippenberg S, Smolders J, Thewissen M, et al. Effect of vitamin D(3) supplementation on peripheral B cell differentiation and isotype switching in patients with multiple sclerosis. Mult Scler. 2011;17(12):1418-1423. doi: 10.1177/1352458511412655
Grund JC, Krammer S, Yang Z, et al. Vitamin D3 resolved human and experimental asthma via B lymphocyte-induced maturation protein 1 in T cells and innate lymphoid cells. J Allergy Clin Immunol Glob. 2023;2(3):100099. doi: 10.1016/J.JACIG.2023.100099
Morgan JW, Sliney DJ, Morgan DM, Maizel AL. Differential regulation of gene transcription in subpopulations of human B lymphocytes by vitamin D3. Endocrinology. 1999;140(1):381-391. doi: 10.1210/ENDO.140.1.6395
Genç D, Sezer Kürkçü M, Günaydin B, Tarhan EF. 1,25-dihydroxyvitamin D3 regulates t helper and b lymphocyte responses substantially in drug-naive primary Sjögren’s syndrome patients’ mononuclear cells. Turk J Med Sci. 2021;51(5):2467-2476. doi: 10.3906/SAG-2103-240
Shirakawa AK, Nagakubo D, Hieshima K, Nakayama T, Jin Z, Yoshie O. 1,25-dihydroxyvitamin D3 induces CCR10 expression in terminally differentiating human B cells. J Immunol. 2008;180(5):2786-2795. doi: 10.4049/JIMMUNOL.180.5.2786
Sharma OP. Vitamin D, calcium, and sarcoidosis. Chest. 1996;109(2):535-539. doi: 10.1378/CHEST.109.2.535
James DG, Neville E, Siltzbach LE. A worldwide review of sarcoidosis. Ann N Y Acad Sci. 1976;278:321-334. doi: 10.1111/j.1749-6632.1976.tb47043.x
Sarathi V, Karethimmaiah H, Goel A. High-dose Vitamin D supplementation precipitating hypercalcemic crisis in granulomatous disorders. Indian J Endocrinol Metab. 2017;21(6):815-819. doi: 10.4103/ijem.IJEM_577_16
Mandell MJ, Kwiatkowski A V, Morse M, et al. Perineural non-caseating granuloma: Red flag or red herring? Journal of Investigative Medicine. 2020;68(5):1049-1050. doi: 10.1136/jim-2020-MW.33
Amrein K, Schilcher G, Fahrleitner-Pammer A. Hypercalcaemia in asymptomatic sarcoidosis unmasked by a vitamin D loading dose. Eur Respir J. 2011;37(2):470-471. doi: 10.1183/09031936.00136910
Nayak-Rao S. Severe hypercalcemia unmasked by Vitamin D in a patient with sarcoidosis. Indian J Nephrol. 2013; 23(5):375-377. doi: 10.4103/0971-4065.116325
Dennis BA, Harper RJ. Splenic sarcoidosis without focal nodularity: A case of 1,25-dihydroxyvitamin d-mediated hypercalcemia localized with FDG PET/CT. Endocr Rev. 2013;34(3):28-33. doi: 10.4158/EP13240.CR
Zhang JTW, Chan C, Kwun SY, Benson KA. A case of severe 1,25-dihydroxyvitamin D-mediated hypercalcemia due to a granulomatous disorder. J Clin Endocrinol Metab. 2012;97(8):2579-2583. doi: 10.1210/jc.2012-1357
Neupane N, Hammoudeh F, Shrestha AL, et al. Sarcoidosis presenting as asymptomatic hypercalcemia. Am J Respir Crit Care Med. 2010;181(1).
Greenblatt HK, Stichman J. “but i feel fine!”: Searching for the cause of asymptomatic hypercalcemia with low pth. J Gen Intern Med. 2021;36(1):S289. doi: 10.1007/s11606-021-06830-5
Belokovskaya R, Mata FP, Davydov O. Sarcoidosis presenting with acute renal failure, hypercalcemia and hyperkalemia. Endocr Rev. 2016;37(2). doi: 10.1210/endo-meetings.2016.BCHVD.16.FRI-330
Abdelnour S, Sharma MD. Inactive sarcoidosis unmasked by an acute presentation of hypercalcemia secondary to milk-alkali syndrome. Endocr Rev. 2012;33(3).
Motoyama K, Inaba M, Emoto M, Morii H, Nishizawa Y. Sarcoidosis initially manifesting as symptomatic hypercalcemia with the absence of organic involvement. Intern Med. 2002;41(6):449-452. doi: 10.2169/internalmedicine.41.449
Aujla K, Majithia V, Green A. Extreme hypercalcemia leading to the diagnosis of extensive sarcoidosis. J Clin Rheumatol. 2014;20(6):328-329. doi: 10.1097/RHU.0000000000000143
Martucci G, Bonicolini E, Parekh D, Thein OS, Scherkl M, Amrein K. Metabolic and Endocrine Challenges. Semin Respir Crit Care Med. 2021;42(1):78-97. doi: 10.1055/s-0040-1713084
Omotosho YB, Zahra F. Resistant Hypercalcemia. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK572109/.Accessed January 5, 2025. Hypercalcemia - Symptoms and causes - Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/hypercalcemia/symptoms-causes/syc-20355523. Accessed January 5, 2025.
Berliner AR, Haas M, Choi MJ. Sarcoidosis: The Nephrologist’s Perspective. American Journal of Kidney Diseases. 2006;48(5):856-870. doi: 10.1053/J.AJKD.2006.07.022/ASSET/0F54EE42-1E56-4574-84D8-F67CE6786F94/MAIN.ASSETS/GR4.SML
Lebacq E, Verhaegen H, Desmet V. Renal involvement in sarcoidosis. Postgrad Med J. 1970;46(538):526-529. doi: 10.1136/PGMJ.46.538.526
Rodman JS, Mahler RJ. Kidney stones as a manifestation of hypercalcemic disorders. Hyperparathyroidism and sarcoidosis. Urol Clin North Am. 2000;27(2):275-285. doi: 10.1016/S0094-0143(05)70257-3
Mayock RL, Bertrand P, Morrison CE, Scott JH. Manifestations of sarcoidosis. Analysis of 145 patients, with a review of nine series selected from the literature. Am J Med. 1963;35(1):67-89. doi: 10.1016/0002-9343(63)90165-7
Rizzato G, Fraioli P, Montemurro L. Nephrolithiasis as a presenting feature of chronic sarcoidosis. Thorax. 1995;50(5):555-559. doi: 10.1136/thx.50.5.555
Vaidya SR, Yarrarapu SNS, Aeddula NR. Nephrocalcinosis. Radiology Illustrated: Uroradiology (Second Edition). 2023;9783642053221:527-549. doi: 10.1007/978-3-642-05322-1_23
Sarathi V, Karethimmaiah H, Goel A. High-dose Vitamin D supplementation precipitating hypercalcemic crisis in granulomatous disorders. Indian J Endocrinol Metab. 2017;21(6):815-819. doi: 10.4103/ijem.IJEM_577_16
Bolland MJ, Wilsher ML, Grey A, et al. Bone turnover and hip bone mineral density in patients with sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2007;26(2):51-58. doi: 10.1186/ar4519
Heijckmann AC, Drent M, Dumitrescu B, et al. Progressive vertebral deformities despite unchanged bone mineral density in patients with sarcoidosis: a 4-year follow-up study. Osteoporos Int. 2008;19(6):839-847. doi: 10.1007/S00198-007-0513-Y
Saidenberg-Kermanac’h N, Semerano L, Nunes H, et al. Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patients. Arthritis Res Ther. 2014;16(2):R78. doi: 10.1186/ar4519
Bours S, de Vries F, van den Bergh JPW, et al. Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort. Osteoporosis International. 2015;27(4):1603. doi: 10.1007/S00198-015-3426-1
Yong WC, Upala S, Sanguankeo A. Bone mineral loss and fracture in sarcoidosis: A systematic review and meta-analysis. Arch Rheumatol. 2019;34(2):130-140. doi: 10.5606/ArchRheumatol.2019.6883
Bolland MJ, Wilsher ML, Grey A, et al. Bone density is normal and does not change over 2 years in sarcoidosis. Osteoporos Int. 2015;26(2):611-616. doi: 10.1007/s00198-014-2870-7
Cameli P, Caffarelli C, Refaie A Al, et al. Evaluation of bone mineral density and fracture risk in sarcoidosis population. Eur Resp J. 2023;62(67):PA1747. Doi: 10.1183/13993003.CONGRESS-2023.PA1747
Baughman RP, Lower EE. Goldilocks, vitamin D and sarcoidosis. Arthritis Res Ther. 2014;16(3). doi: 10.1186/ar4568
Filipovic S, Violeta V, Jelica V, Mihailo S, Aleksandar J. Vitamin D deficiency and activity of sarcoidosis. European Respiratory Journal. 2016;48. doi: 10.1183/13993003.congress-2016.PA827
Scullion T, Davidson L, Murtagh E, Minnis P. The role of Vitamin D in pulmonary sarcoidosis and inflammation. Thorax. 2021;76(1):A160. doi: 10.1136/thorax-2020-BTSabstracts.277
Kavathia D, Buckley JD, Rao D, Rybicki B, Burke R. Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir Med. 2010;104(4):564-570. doi: 10.1016/j.rmed.2009.12.004
Mihailović-Vucinic V, Ignjatović S, Dudvarski-Ilić A, et al. The role of vitamin D in multisystem sarcoidosis. J Med Biochem. 2012;31(4):339-346. doi: 10.2478/v10011-012-0015-0
Kamphuis LS, Bonte-Mineur F, van Laar JA, van Hagen PM, van Daele PL. Calcium and vitamin D in sarcoidosis: is supplementation safe? J Bone Miner Res. 2014;29(11):2498-2503. doi: 10.1002/jbmr.2262
Kiani A, Abedini A, Adcock IM, et al. Association Between Vitamin D Deficiencies in Sarcoidosis with Disease Activity, Course of Disease and Stages of Lung Involvements. 2018;37(2):103-109. doi: 10.1515/JOMB-2017-0041
Gwadera Ł, Białas AJ, Kumor-Kisielewska A, Miłkowska-Dymanowska J, Majewski S, Piotrowski WJ. Calcium, Phosphate, and Vitamin D Status in Patients with Sarcoidosis-Associations with Disease Activity and Symptoms. J Clin Med. 2023;12(14):4745. doi: 10.3390/JCM12144745
Bolland MJ, Wilsher ML, Grey A, et al. Randomised controlled trial of vitamin D supplementation in sarcoidosis. BMJ Open. 2013;3(10):e003562. doi: 10.1136/bmjopen-2013-003562
Capolongo G, Xu LHR, Accardo M, et al. Vitamin-D status and mineral metabolism in two ethnic populations with sarcoidosis. J Investig Med. 2016;64(5):1025-1034. doi: 10.1136/jim-2016-000101
Sodhi A, Aldrich T. Vitamin D Supplementation: Not So Simple in Sarcoidosis. Am J Med Sci. 2016;352(3):252-257. doi: 10.1016/j.amjms.2016.05.027
Gianella F, Hsia CC, Sakhaee K. The role of vitamin D in sarcoidosis. Fac Rev. 2020;9:14. doi:10.12703/b/9-14
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
